10021 Results for "

value

" in MedChemExpress (MCE) Product Catalog:
Products (10021)

10021 Results for "value" in MCE Product Catalog:

100
100 Cited Publications
Cat. No.: HY-50898
CAS No.: 231277-92-2
Synonyms: GW572016; GW2016
Lapatinib (GW572016) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
loading...
    loading...
100
100 Cited Publications
Cat. No.: HY-50898A
CAS No.: 388082-77-7
Synonyms: GW572016 ditosylate; GW2016 ditosylate
Lapatinib ditosylate (GW572016 ditosylate) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
loading...
    loading...
100
100 Cited Publications
Cat. No.: HY-50898B
CAS No.: 388082-78-8
Synonyms: GW572016 ditosylate monohydrate; GW2016 ditosylate monohydrate
Target:  

EGFR Autophagy Ferroptosis

Research Areas:  

Infection Metabolic Disease Cancer

Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .
loading...
    loading...
100
100 Cited Publications
Cat. No.: HY-13803
CAS No.: 1403254-99-8
Purity:  99.93%
Synonyms: EPZ-6438; E-7438
Research Areas:  

Cancer

Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC50 of 4 nM. Tazemetostat also inhibits EZH1 with an IC50 of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells .
loading...
    loading...
97
97 Cited Publications
Cat. No.: HY-10331
CAS No.: 755037-03-7
Purity:  99.93%
Synonyms: BAY 73-4506
Research Areas:  

Cancer

Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .
loading...
    loading...
97
97 Cited Publications
Cat. No.: HY-10331A
CAS No.: 1019206-88-2
Purity:  99.96%
Synonyms: BAY 73-4506 monohydrate
Research Areas:  

Cancer

Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .
loading...
    loading...
95
95 Cited Publications
Cat. No.: HY-12071
CAS No.: 1062368-24-4
Purity:  99.41%
Synonyms: DM-3189
Research Areas:  

Cancer

LDN193189 (DM-3189) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .
loading...
    loading...
95
95 Cited Publications
Cat. No.: HY-12071A
CAS No.: 2310134-98-4
Purity:  99.79%
Synonyms: DM-3189 Tetrahydrochloride
Research Areas:  

Cancer

LDN193189 (DM-3189) Tetrahydrochloride is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .
loading...
    loading...
95
95 Cited Publications
Cat. No.: HY-12071B
CAS No.: 1435934-00-1
Purity:  99.75%
Synonyms: DM-3189 dihydrochloride
Research Areas:  

Cancer

LDN193189 (DM-3189) dihydrochloride is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .
loading...
    loading...
87
87 Cited Publications
Cat. No.: HY-18729A
CAS No.: 51298-62-5
Synonyms: NG-Nitroarginine methyl ester hydrochloride
Target:  

NO Synthase

Research Areas:  

Infection Neurological Disease Cancer

L-NAME hydrochloride inhibits NOS with an IC50 of 70 μM. L-NAME is a precursor to NOS inhibitor L-NOARG which has an IC50 value of 1.4 μM. L-NAME hydrochloride requires hydrolysis of the methyl ester by cellular esterases to become a fully functional inhibitor. L-NAME hydrochloride can be used to induce hypertension and preeclampsia models.
loading...
    loading...
86
86 Cited Publications
Cat. No.: HY-15777
CAS No.: 1211441-98-3
Purity:  99.94%
Synonyms: LEE011
Target:  

CDK

Research Areas:  

Neurological Disease Cancer

RRibociclib (LEE011) is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .
loading...
    loading...
86
86 Cited Publications
Cat. No.: HY-15777A
CAS No.: 1211443-80-9
Purity:  99.93%
Synonyms: LEE011 hydrochloride
Target:  

CDK

Research Areas:  

Neurological Disease Cancer

RRibociclib (LEE011) hydrochloride is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .
loading...
    loading...
86
86 Cited Publications
Cat. No.: HY-15777B
CAS No.: 1374639-75-4
Purity:  99.93%
Synonyms: LEE011 succinate
Target:  

CDK

Research Areas:  

Neurological Disease Cancer

RRibociclib (LEE011) succinate is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .
loading...
    loading...
86
86 Cited Publications
Cat. No.: HY-15777C
CAS No.: 1374639-79-8
Purity:  99.94%
Synonyms: LEE011 succinate hydrate
Target:  

CDK

Research Areas:  

Cancer

RRibociclib (LEE011) succinate hydrate is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .
loading...
    loading...
85
85 Cited Publications
Cat. No.: HY-14397
CAS No.: 53-86-1
Purity:  99.91%
Synonyms: Indometacin
Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research .
loading...
    loading...
85
85 Cited Publications
Cat. No.: HY-14397A
CAS No.: 74252-25-8
Purity:  99.85%
Synonyms: Indometacin sodium hydrate
Indomethacin (Indometacin) sodium hydrateis a orally active and BBB-permeable COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin sodium hydrateis has anticancer activity and anti-infective activity. Indomethacin sodium hydrateis can be used for cancer, inflammation and viral infection research .
loading...
    loading...
82
82 Cited Publications
Cat. No.: HY-12071C
CAS No.: 1062368-62-0
Synonyms: DM-3189 hydrochloride
LDN193189 (DM-3189) hydrochloride is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .
loading...
    loading...
71
71 Cited Publications
Cat. No.: HY-15174
CAS No.: 1028385-32-1
Purity:  99.87%
Synonyms: BEZ235 Tosylate; NVP-BEZ 235 Tosylate
Target:  

PI3K mTOR Autophagy

Research Areas:  

Cancer

Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.
loading...
    loading...
69
69 Cited Publications
Cat. No.: HY-15186
CAS No.: 1001264-89-6
Purity:  99.79%
Synonyms: GDC-0068; RG7440
Target:  

Organoid Akt Apoptosis

Research Areas:  

Cancer

Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models .
loading...
    loading...
67
67 Cited Publications
Cat. No.: HY-50876
CAS No.: 658084-64-1
Synonyms: FK866; APO866
Research Areas:  

Cancer

Daporinad (FK866) is a non-competitive inhibitor of nicotinamide phosphoribosyltransferase (Nampt), with a Ki value of 0.3 nM. Daporinad depletes NAD+ and ATP levels, inhibits mTORC1 and MAPK/ERK pathways, and activates TFEB to induce autophagy. Daporinad causes the depletion of the endoplasmic reticulum Ca²⁺ pool, ultimately weakening the mitogen-induced Ca²⁺ signal and the activation and function of T cells. Daporinad induces cell cycle arrest and apoptosis, and inhibits cell proliferation. Daporinad can be used for the study of myeloma, liver cancer, and immunosuppression .
loading...
    loading...